We are live on ! Find out more
SCM

Sarissa Capital Management Portfolio holdings

AUM $158M
1-Year Est. Return 103.7%
This Fund
S&P 500
This Quarter Est. Return
-1.47%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$323M
AUM Growth
-$79.5M
Cap. Flow
-$73.9M
Cap. Flow %
-22.9%
Top 10 Hldgs %
100%
Holding
10
New
–
Increased
1
Reduced
3
Closed
2

Top Buys

Rank Stock Value
1
LNTH icon
Lantheus
LNTH
+$3.6M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$45.1M
2
CYTK icon
Cytokinetics
CYTK
+$14.3M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$12.5M
4
BIIB icon
Biogen
BIIB
+$5.22M
5
RGLS
Regulus Therapeutics
RGLS
+$291K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INVA icon
1
Innoviva
INVA
$1.55B
$126M 39.11%
7,277,000
– –
IRWD icon
2
Ironwood Pharmaceuticals
IRWD
$696M
$72.6M 22.49%
16,390,000
– –
NBIX icon
3
Neurocrine Biosciences
NBIX
$16.8B
$42.2M 13.07%
309,116
-101,367
-25% -$12.5M
CYTK icon
4
Cytokinetics
CYTK
$10.5B
$39.2M 12.15%
833,799
-276,201
-25% -$14.3M
GILD icon
5
Gilead Sciences
GILD
$162B
$24.2M 7.5%
262,080
-501,253
-66% -$45.1M
AMRN
6
Amarin Corp
AMRN
$299M
$12.1M 3.73%
1,242,531
– –
LNTH icon
7
Lantheus
LNTH
$6.49B
$5.64M 1.75%
63,000
+37,000
+142% +$3.6M
VOR icon
8
Vor Biopharma
VOR
$1.15B
$686K 0.21%
30,900
– –
BIIB icon
9
Biogen
BIIB
$30B
– –
-26,950
Closed -$5.22M
RGLS
10
DELISTED
Regulus Therapeutics
RGLS
– –
-185,183
Closed -$291K

Similar funds

4A
4D Advisors Redondo Beach, California $158M AUM 92.73% 1-Year Est. Return
DAM
Deepwater Asset Management Minneapolis, Minnesota $158M AUM 23.9% 1-Year Est. Return
PCP
Pantera Capital Partners San Francisco, California $158M AUM 600.89% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $157M AUM
HEM
Henson-Edgewater Management Avon, Ohio $157M AUM
SF
Seros Financial Tempe, Arizona $157M AUM 16.95% 1-Year Est. Return
AC
AlpenGlobal Capital Tahoe City, California $157M AUM
EP
Elkhorn Partners Omaha, Nebraska $157M AUM 11.91% 1-Year Est. Return

Sarissa Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, Sarissa Capital Management held 10 positions worth $323M, down 20% from $402M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Sarissa Capital Management withdrew a net $73.9M in Q4 2024, closing 2 positions and reducing 3 holdings. Its most notable exit was Biogen, an estimated $5.22M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Sarissa Capital Management added an estimated $3.6M to Lantheus.

  • Sarissa Capital Management added most to Lantheus in Q4 2024, an estimated $3.6M increase.
  • Sarissa Capital Management's biggest Q4 2024 reduction was Gilead Sciences, cutting an estimated $45.1M.
  • Sarissa Capital Management fully exited Biogen in Q4 2024, selling an estimated $5.22M.
  • Sarissa Capital Management's ten largest holdings make up 100% of its $323M portfolio in Q4 2024.
  • Sarissa Capital Management opened 0 new positions and closed 2 in Q4 2024.
  • Sarissa Capital Management's portfolio value fell 20% quarter-over-quarter to $323M.

Based on Sarissa Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.